Buspirone Hydrochloride (Buspar) + Lisdexamfetamine Dimesylate (Vyvanse)
FDA label language suggests this combination may require monitoring, dose adjustment, or added caution. Make sure every prescriber involved in your care knows you take both.
Basis: Warnings section — monitoring/caution language of the Lisdexamfetamine Dimesylate FDA label.
Further clinical evaluation (e.g., rheumatology referral) may be appropriate for lisdexamfetamine dimesylate capsule -treated patients who develop signs or symptoms of peripheral vasculopathy. 5.7 Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serot
Excerpt from the FDA prescribing label for Lisdexamfetamine Dimesylate (SPL set ID 0e024b69-567c-4b40-9c3e-a2daec34256c).
About this interaction data. These interactions were identified by automatically scanning FDA prescribing-label text for medications in Bridgeway's library. This is not a complete list and is not a substitute for review by your prescriber or pharmacist, who use comprehensive clinical databases. Always share your full medication list with your care team. How we source this data →
Bridgeway's Utah prescribers coordinate medication management with therapy — so interactions like this one are reviewed by people who see your whole picture.
Request an Appointment Call (801) 255-5131Not medical advice. This page summarizes publicly available FDA drug labeling alongside general guidance from Bridgeway Integrated Healthcare Services. It is for educational purposes only and is not a substitute for advice from your prescriber or pharmacist. Never start, stop, or change a medication without talking to your healthcare provider. In an emergency, call 911.